Co-Authors
This is a "connection" page, showing publications co-authored by GUILLERMO GARCIA-MANERO and JOSEPH KHOURY.
Connection Strength
3.985
-
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
Score: 0.203
-
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
Score: 0.201
-
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53.
Score: 0.197
-
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Adv. 2018 10 09; 2(19):2491-2504.
Score: 0.170
-
Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv. 2018 08 14; 2(15):1807-1816.
Score: 0.169
-
Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. Am J Surg Pathol. 2018 06; 42(6):799-806.
Score: 0.166
-
Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica. 2017 10; 102(10):1661-1670.
Score: 0.156
-
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
Score: 0.149
-
TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. 2015 Oct; 171(1):91-9.
Score: 0.136
-
Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S85-90.
Score: 0.135
-
Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. J Hematol Oncol. 2014 Mar 27; 7:26.
Score: 0.124
-
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol. 2014 May; 89(5):499-504.
Score: 0.123
-
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024 Mar 29.
Score: 0.062
-
Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma. Am J Hematol. 2024 Mar 05.
Score: 0.062
-
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. medRxiv. 2023 Dec 09.
Score: 0.061
-
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.
Score: 0.061
-
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
Score: 0.059
-
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444.
Score: 0.059
-
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol. 2023 06; 36(6):100166.
Score: 0.058
-
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2022 Nov 16.
Score: 0.057
-
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014.
Score: 0.055
-
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022 05 24; 6(10):3027-3035.
Score: 0.055
-
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol. 2022 09; 35(9):1212-1219.
Score: 0.055
-
Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022 07; 97(7):865-876.
Score: 0.054
-
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022 03 01; 97(3):329-337.
Score: 0.053
-
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 12 14; 5(23):5415-5419.
Score: 0.053
-
Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021 10 14; 138(15):1373-1377.
Score: 0.053
-
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389.
Score: 0.051
-
Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harb Mol Case Stud. 2021 06; 7(3).
Score: 0.051
-
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656.
Score: 0.051
-
Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038.
Score: 0.050
-
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 05 01; 96(5):589-598.
Score: 0.050
-
Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213.
Score: 0.050
-
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):338-344.
Score: 0.050
-
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228.
Score: 0.049
-
Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2021 05; 16(5):567-576.
Score: 0.049
-
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.
Score: 0.048
-
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739.
Score: 0.047
-
Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 09; 33(9):1678-1689.
Score: 0.047
-
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
Score: 0.047
-
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
Score: 0.046
-
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.
Score: 0.044
-
A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma. 2019 09; 60(9):2207-2213.
Score: 0.044
-
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e618-e627.
Score: 0.043
-
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055.
Score: 0.043
-
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
Score: 0.041
-
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
Score: 0.040
-
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol. 2017 Dec; 44(12):1075-1079.
Score: 0.040
-
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724.
Score: 0.039
-
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117.
Score: 0.038
-
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302.
Score: 0.037
-
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.
Score: 0.037
-
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555.
Score: 0.035
-
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol. 2014 Aug; 89(8):813-8.
Score: 0.031